Solidly Positive Phase III Data Boost Keryx’ Struggling Iron Drug Auryxia

Keryx set to pursue expanded FDA labeling of its phosphate binder Auryxia to pre-dialysis patients with iron deficiency, a patient population already approved for treatment in Europe.